
Akerna Corp. KERN
Annual report 2025
added 03-27-2026
Akerna Corp. Cost of Revenue 2011-2026 | KERN
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Akerna Corp.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 92 M | 39.5 M | 43.6 M | 4.91 M | 8.12 M | 4.39 M | 4.63 M | 4.36 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 92 M | 4.36 M | 25.2 M |
Quarterly Cost of Revenue Akerna Corp.
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 28.3 M | 1.61 M | 2.05 M | - | 11.1 M | 3.8 M | 4.84 M | - | 3.98 M | 2.82 M | 1.05 M | - | 1.48 M | 1.18 M | 1.52 M | - | 1.97 M | 1.91 M | 1.45 M | - | 1.74 M | 1.82 M | 1.74 M | 1.62 M | 1.38 M | 1.64 M | 1.4 M | 1.32 M | 1.06 M | - | 818 K | 1.15 M | 1.36 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 28.3 M | 818 K | 3.19 M |
Cost of Revenue of other stocks in the Health information services industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Accolade
ACCD
|
93.7 M | - | 0.29 % | $ 206 M | ||
|
Cerner Corporation
CERN
|
1 B | - | - | $ 27.9 B | ||
|
Computer Programs and Systems
CPSI
|
176 M | - | 4.4 % | $ 133 M | ||
|
Covetrus
CVET
|
3.72 B | - | - | $ 2.94 B | ||
|
iCAD
ICAD
|
2.97 M | - | - | $ 102 M | ||
|
Evolent Health
EVH
|
1.04 B | $ 2.52 | -0.59 % | $ 236 M | ||
|
GoodRx Holdings
GDRX
|
48.2 M | $ 2.22 | 3.26 % | $ 856 M | ||
|
SCWorx Corp.
WORX
|
1.96 M | - | - | $ 7.71 M | ||
|
Allscripts Healthcare Solutions
MDRX
|
883 M | - | -10.39 % | $ 886 M | ||
|
NextGen Healthcare
NXGN
|
275 M | - | - | $ 1.6 B | ||
|
1Life Healthcare
ONEM
|
319 M | - | - | $ 3.37 B | ||
|
10x Genomics
TXG
|
209 M | $ 24.6 | 4.33 % | $ 2.88 B | ||
|
OptimizeRx Corporation
OPRX
|
28.6 M | $ 5.95 | 0.34 % | $ 102 M | ||
|
Health Catalyst
HCAT
|
159 M | $ 1.1 | 3.3 % | $ 76.9 M | ||
|
HealthEquity
HQY
|
400 M | $ 80.27 | 0.45 % | $ 6.91 B | ||
|
Premier
PINC
|
269 M | - | - | $ 2.33 B | ||
|
Schrödinger
SDGR
|
113 M | $ 11.79 | 2.97 % | $ 866 M | ||
|
Phreesia
PHR
|
71.4 M | $ 8.6 | 0.47 % | $ 514 M | ||
|
R1 RCM
RCM
|
1.16 B | - | - | $ 3.81 B | ||
|
Teladoc Health
TDOC
|
772 M | $ 5.22 | - | $ 920 M | ||
|
Signify Health
SGFY
|
440 M | - | -0.02 % | $ 7.21 B | ||
|
NantHealth
NH
|
28.8 M | - | -46.64 % | $ 10.4 M | ||
|
American Well Corporation
AMWL
|
116 M | $ 5.47 | -1.44 % | $ 87.8 M | ||
|
Tabula Rasa HealthCare
TRHC
|
233 M | - | - | $ 255 M | ||
|
HealthStream
HSTM
|
97.9 M | $ 20.49 | 0.59 % | $ 623 M | ||
|
Omnicell
OMCL
|
641 M | $ 36.28 | 3.61 % | $ 1.67 B | ||
|
Progyny
PGNY
|
235 M | $ 16.86 | -0.68 % | $ 1.45 B | ||
|
So-Young International
SY
|
568 M | $ 2.75 | 2.23 % | $ 218 M | ||
|
Veeva Systems
VEEV
|
782 M | $ 157.03 | -0.9 % | $ 25.7 B | ||
|
Zhongchao
ZCMD
|
6.25 M | $ 1.99 | -1.24 % | $ 6.8 M |